This announcement is a separate document:
開拓藥業-B：自願公告 ALK-1單抗聯合KN046治療晚期或難治性實體腫瘤臨床試驗完成首例患者給藥
KINTOR PHARMA-B: VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSING IN TRIAL OF ALK-1 IN COMBINATION WITH KN046 IN ADVANCED OR REFRACTORY SOLID TUMORS
Nov 2, 2021 17:42
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.